EP0739356B1 - Anticorps polyclonal contre des complexes anp/acide nucleique - Google Patents

Anticorps polyclonal contre des complexes anp/acide nucleique Download PDF

Info

Publication number
EP0739356B1
EP0739356B1 EP95904403A EP95904403A EP0739356B1 EP 0739356 B1 EP0739356 B1 EP 0739356B1 EP 95904403 A EP95904403 A EP 95904403A EP 95904403 A EP95904403 A EP 95904403A EP 0739356 B1 EP0739356 B1 EP 0739356B1
Authority
EP
European Patent Office
Prior art keywords
pna
nucleic acid
dna
complex
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP95904403A
Other languages
German (de)
English (en)
Other versions
EP0739356A1 (fr
Inventor
Jens Jorgen Hyldig-Nielsen
Karl-Johan Pluzek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dako Denmark ApS
Original Assignee
Dako AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dako AS filed Critical Dako AS
Publication of EP0739356A1 publication Critical patent/EP0739356A1/fr
Application granted granted Critical
Publication of EP0739356B1 publication Critical patent/EP0739356B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Definitions

  • This invention relates to polyclonal antibodies to complexes formed between PNA ( P eptide N ucleic A cid) and nucleic acids.
  • PNAs Peptide Nucleic Acids
  • PNA oligomers have a surprising high affinity for complementary nucleic acid forming very stable and specific complexes. This property makes such PNA oligomers suitable as hybridization probes for detection of nucleic acids.
  • the usability of PNA as hybridization probes is greatly increased by the present antibodies.
  • the antibodies according to the invention are useful in the capture, recognition, detection, identification or quantitation of nucleic acids in biological samples, via their ability to react with PNA-nucleic acid complexes.
  • the capture, recognition, detection, identification or quantitation of one or more chemical or biological entities is useful in the fields of recombinant DNA, human and veterinary medicine, agriculture and food science, among others.
  • these techniques can be used to detect and identify etiological agents such as bacteria and vira, to screen bacteria for antibiotic resistance, to aid in the diagnosis of genetic disorders and to detect cancerous cells.
  • the state-of-the-art nucleic acid hybridization assay techniques generally involve hybridization with a labelled form of a complementary polynucleotide probe. Hybridization between particular base sequences or genes of interest in the sample nucleic acid and labelled probe is determined by detection of the labelled hybrids.
  • the preparation of labelled probe generally involves the enzymatic incorporation of radiolabelled or modified nucleotides or chemical modification of the probe to attach or form a detectable chemical group. Preparation of labelled probes is often time consuming and expensive and has to be carried out without destroying the ability of the probe to detectably hybridize with its complementary sequence.
  • polyclonal antisera may contain antibodies that will cross-react with single-stranded nucleic acid.
  • Polyclonal antisera may also contain naturally occurring antibodies to single-stranded nucleic add or antibodies to single-stranded nucleic acid arising as a result of the immunization.
  • Monoclonal antibody technology can provide a means to select an antibody with desired affinity and specificity which will overcome the problems discussed above.
  • Such monoclonal antibodies which will selectively bind double-stranded DNA (US 4,623,627) or DNA-RNA hybrids (US 4,833,084) have been prepared and used in the detection of duplexes formed between particular base sequences of interest in the sample nucleic acid and a probe with a known complementary sequence.
  • nucleic acid analoque PNA Peptide Nucleic Acid
  • PNAs Peptide Nucleic Acids
  • WO 92/20702 compounds comprising a polyamide backbone bearing a plurality of ligands such as naturally occurring nucleobases attached to a polyamide backbone through a suitable linker. It has recently been shown that PNA in which the backbone is structurally homomorphous with the deoxyribose backbone and consists of N-(2-aminoethyl)glycin units to which the nucleobases are attached can hybridize to complementary oligonucleotides to form PNA-nucleic acid complexes (Egholm et al., Nature, vol 365, 566-565 (1993)).
  • One aspect of the present invention is polyclonal antibodies that binds to complexes formed between PNA and nucleic acids.
  • PNA/nucleic add complexes and nucleic acid duplexes possess substantially different properties in that the PNA of a PNA/nucleic acid complex has a backbone consisting of an N-(2-aminoethyl)glycin oligomer or polymer which is achiral and non charged as opposed to the corresponding strands of an nucleic add duplex, wherein the backbone is a sequence of nucleotides containing one anion for each phosphate group.
  • polyclonal antibodies that binds to complexes formed between PNA and DNA or PNA and RNA.
  • polyclonal antibodies to complexes formed between PNA and nucleic adds do not bind to single-stranded PNA, double-stranded nucleic acid or single-stranded nucleic acid.
  • the antibody binds to a complex formed between PNA and DNA, but not to PNA/RNA complexes, double-stranded DNA, DNA/RNA hybrids, single-stranded PNA or single-stranded nucleic acid.
  • the antibody binds to a complex formed between PNA and RNA, but not to PNA/DNA complexes, double-stranded DNA, DNA/RNA hybrids, single-stranded PNA or single-stranded nucleic acid.
  • Polyclonal antibodies that binds to PNA/nucleic acid complexes irrespective of the base sequence are also part of the invention.
  • Polyclonal antibodies of the present invention can be obtained by immunizing a host animal with a complex formed by contacting PNA with a nucleic acid, particularly a complex formed between PNA with a backbone of N-(2-aminoethyl)glycin units and DNA or RNA.
  • Various methods for detecting a particular nucleic acid sequence in a test sample are additional aspects of the invention, whereby the antibodies according to the invention can be used in the capture, recognition, detection, identification or quantitation of one or more chemical or biological entities.
  • the antibodies are very useful in the human and veterinary field. Especially contemplated is the use of the present antibodies to detect the presence or amount of infectious agents in humans such as chlamydial or gonococcal organisms or infections with Epstein Barr virus or papillomavirus.
  • the present antibodies are also useful in the general field of cytogenetics such as chromosomal painting.
  • the invention also provides a kit containing an antibody according to the invention, which antibody might be in a detectably labelled form, a PNA sequence that is complementary to the nucleic acid sequence to be detected and a detection system.
  • antibody of the present invention it is intended to include whole, intact antibodies, antibody fragments, polyfunctional antibody aggregates, or in general any antibody-derived substance that comprises at least one antibody combining site having the characteristics described herein.
  • Antibodies of any of the known classes and subclasses of immunoglobulins are contemplated, e.g., IgG, IgM, and so forth, as well as active fragments such as the Ig fragments conventionally known as scFv, Fab, F(ab'), and F(ab') 2 .
  • nucleic acid covers a nucleotide polymer composed of subunits, which are either deoxyribonucleosides or ribonucleosides joined together by phosphodiester bridges between the 5'-position of one nucleoside and the 3'-position of another nucleoside. They may be DNA or various types of RNA.
  • bases and nucleobases are used interchangeable for pyrimidine and purine bases of the nucleic acids and PNA.
  • the PNAs are synthesized according to the procedure described in "Improved Synthesis, Purification and Characterization of PNA Oligomers", Presented at the 3rd Solid-Phase Symposium, Oxford UK, Aug. 31 - Sept. 4, 1994.
  • the PNA-nucleic acid complex used for immunization of an animal according to the present invention might comprise PNA and DNA or RNA. Since both nucleic acid and PNA are devoid of diversed peptide sources, both nucleic acid duplexes and PNA/nucleic acid complexes would be expected to be essentially non-immunogenic in normal host animals (i.e. animal which are not prone to generate auto-antibodies against nucleic acid) when injected per se .
  • antibodies against PNA/DNA complexes can be raised by immunizing a normal host animal with a mixture comprising a PNA/DNA complex and a non-derivatized protein heterologous to the host animal, such as ovalbumin.
  • This technology can be applied to immunization with PNA/RNA complexes.
  • a PNA-DNA complex can be prepared by contacting double-stranded or single-stranded DNA with a PNA molecule having a base sequence that is complementary to all or part of the DNA sequence, heating the mixture to form single-stranded molecules and allowing the mixture to cool slowly to room temperature.
  • a PNA-RNA complex can be prepared by contacting RNA with a PNA molecule having a base sequence that is complementary to all or part of the RNA sequence, heating the mixture and allowing the mixture to cool slowly to room temperature.
  • a suitable quantity of one of the PNA-nucleic acid complexes is mixed with an adjuvant.
  • the immunogen might be used unconjugated or conjugated to a suitable carrier such as KLH (Keyhole Limpet Hemocyanin), ovalbumin and dextrans.
  • Polyclonal antibodies of the present invention were obtained by immunizing rabbits with a mixture of a PNA/DNA complex, wherein the PNA had a N-(2-aminoethyl)glycin backbone, ovalbumin and a suitable adjuvant. The immunization schedule and bleeding were otherwise performed as described by Harboe and Ingild, Scand. J. Immunol., vol 17, Suppl. 10, 345-351, 1983. Polyclonal antibodies with a high specificity for PNA/DNA complexes were obtained from the serum of the immunized rabbits. Many animals are suitable as host animals for the production of polyclonal antibodies.
  • the polyclonal antibodies raised against a complex of PNA and a 45-mer DNA reacted strongly with PNA/DNA and PNA/RNA complexes and not with double-stranded DNA, DNA/RNA-hybrids, single-stranded DNA or single-stranded PNA.
  • the antibody reacted strongly with four different PNA/DNA complexes wherein the base sequence was different indicating that the antibodies recognize the conformation of the PNA/DNA complex rather than any specific base sequence in the PNA or DNA.
  • Polyclonal antibodies of the present invention can be obtained by immunizing rabbits with a mixture of a PNA/RNA complex, wherein the PNA had a N-(2-aminoethyl)glycin backbone, ovalbumin and a suitable adjuvant.
  • the immunization schedule and bleeding are otherwise performed as described by Harboe and Ingild, Scand. J. Immunol., vol 17, Suppl. 10, 345-351, 1983. Many animals are suitable as host animals for the production of polyclonal antibodies.
  • the antibodies of the present invention are characterized by a high degree of specificity for PNA-nucleic acid complexes. They do not to any significant degree bind to double-stranded nucleic acid, single-stranded PNA or single-stranded nucleic acid.
  • the specificity of the epitope(s) recognized by the present antibodies appears to be dictated by the conformation of the PNA-nucleic acid complex rather than by any specific sequence of the PNA or the nucleic acid.
  • a high specificity and affinity of the antibodies according to the invention give significant advantages when used in the isolation, detection and quantitation of PNA-nucleic acid complexes formed between PNA and nucleic acid to be detected in a biological sample.
  • the antibodies with a high specificity for PNA/DNA complexes are particularly valuable in DNA probe based analysis for identifying infectious agents in humans such as chlamydial or gonoccal organims.
  • These antibodies are also very useful in the general field of cytogenetics such as chromosome painting.
  • Antibodies according to the invention having a high specificity and affinity for PNA/RNA complexes are particularly useful in RNA probe based analysis, for example for identifying mRNA or rRNA sequences specific for particular organisms.
  • the antibody may be coupled with a detectable label such as enzymatically active groups like coenzymes, enzyme inhibitors and enzymes themselves, fluorescers, chromophores, luminescers, specifically bindable ligands such as biotin or haptens.
  • a detectable label such as enzymatically active groups like coenzymes, enzyme inhibitors and enzymes themselves, fluorescers, chromophores, luminescers, specifically bindable ligands such as biotin or haptens.
  • the antibodies according to the invention are valuable tools in a number of different methods for detecting a particular nucleic acid sequence, such as a method comprising
  • the PNA sequence in (a) can be immobilized to a solid phase prior to the contact with the nucleic acid sequence to be detected or the antibody used in (b) can be immobilized to a solid phase prior to contact with the PNA-nucleic acid complex.
  • nucleic acid sequences to be detected exists in an immobilized state in a biological specimen, a method comprising
  • the initial step could be an immobilization of the nucleic acid sequence to be detected in a method comprising
  • a kit for carrying out the described methods or other methods taking advantage of the antibodies according to the present invention contains in addition to the present antibody in labelled or unlabelled form, a PNA sequence that is complementary to the nucleotide sequence to be detected, i.e. a PNA probe, and a detection system.
  • the detection system may comprise an enzyme which is able to react with a substrate to form a coloured soluble or insoluble reaction product.
  • a polynucleotide sequence of interest can be determined in solution by contact with PNA molecules complementary to the sequence of interest followed by contact with an antibody according to the present invention, recognizing the PNA-nucleic acid complexes but not free PNA or nucleic acids. These reactions will result in a large complex which may be detected e.g. in a turbidimetric assay format.
  • a polynucleotide sequence of interest can be determined by contacting it with a PNA-oligomer complementary to the sequence of interest.
  • the complexes formed are, while still in solution, contacted with an antibody according to the present invention in a labelled or unlabelled form.
  • the PNA-nucleic acid-antibody complex formed is then captured using e.g. an antibody according to the present invention which has been immobilized on a solid phase. Unbound materials are washed off and the amount of bound PNA-nucleic acid-antibody complex is determined either via the label on the antibody or by using a secondary antibody detection system, provided that the immobilized antibody is derived from an alternative species from that of the detecting antibody.
  • the PNA-oligomers complementary to the sequence of interest may be labelled with a moiety e.g. biotin, fluorescein, or other haptens which is suitable for catching of PNA-nucleic acid complexes. Unbound materials are washed off and the amount of bound PNA-nucleic add-antibody complex is determined either via a label on the antibody or by using a secondary antibody detection system.
  • a moiety e.g. biotin, fluorescein, or other haptens which is suitable for catching of PNA-nucleic acid complexes. Unbound materials are washed off and the amount of bound PNA-nucleic add-antibody complex is determined either via a label on the antibody or by using a secondary antibody detection system.
  • a traditional capture assay consists of the following steps recognition, capture, detection. Such assays may be build up in many different ways. One particular interesting example is outlined below.
  • An antibody capable of binding a PNA-nucleic acid complex is coupled or alternative immobilized to a solid support, e.g. an ELISA plate.
  • PNA oligomers and sample are mixed and allowed to react in solution in the wells of the ELISA-plate. If complexes between the PNA and the sample nucleic acids are formed, these complexes are captured by the immobilized antibody. Unbound materials are washed off, and to ensure available binding sites for the detection system PNA-oligomers can be added and allowed to react with the bound nucleic acids.
  • An antibody of this invention e.g. conjugated with an enzyme, is added and allowed to react with the formed PNA-nucleic acid complexes. After washing a suitable enzyme substrate is added and the amount of bound materials is measured.
  • moieties could e.g. be biotinylated PNA-oligomers or PNA-oligomers labelled with other haptens, peptides,or polypeptides.
  • Complexes formed between a PNA-oligomer and nucleic acids in which either the PNA or the nucleic acid initially was immobilized on a solid phase can be detected by the antibody of the present invention.
  • This detection can be performed either directly using an antibody conjugated to an enzyme, a fluorescent marker or an other signal generating system, or indirectly using one of the secondary detection systems commonly used for detecting antibodies bound to their target.
  • the solid phase considered should be understood in a very broad sense like e.g. nylon or nitrocellulose membranes (Southern or Northern blots), a tissue section ( in situ hybridization), or a plastic surface (an ELISA format).
  • This system has the advantage that the normally very extensive washing procedures included in these technologies can be reduced to a minimum as unspecific bound PNA-oligomers, being single-stranded, will not give rise to a signal as the antibody only recognizes PNA hybridized to nucleic acids. For the same reason this type of analysis will result in less problems with back-ground caused by unspecific binding of the PNA-oligomer.
  • SPR surface plasmon resonance
  • BIAcore biosensor system Pharmacia
  • the interaction of biomolecules with an immobilized ligand on a sensor chip is measured at the surface using evanescent light.
  • the system includes a sensor chip to which the ligand can be immobilized in a hydrophilic dextran matrix, a miniaturised fluidics cartridge for the transport of analytes and reagents to the sensor surface, a SPR detector, an autosampler and system control and evaluation software.
  • Specific ligands are covalently immobilized to the sensor chip through amine, thiol or aldehyde chemistry or biospecifically by e.g. biotin - avidin interaction.
  • the antibody of this invention is coupled to the dextran layer of a sensor chip used in the BIAcore biosensor-system (or other types of biosensor systems).
  • a sample is mixed with a PNA-oligomer and incubated so that a complex is formed between PNA and sample nucleic acids complementary to the PNA-oligomer used.
  • the sample is passed through the flow system of the BIAcore and the antibody coupled to the dextran surface will bind the PNA-nucleic acid complexes if such complexes have been formed. Based on the SPR detection employed by the BIAcore this binding will generate a signal dependent on the amount of materials bound to the surface.
  • PNA oligomers may be able to penetrate the cell-wall of living or fixed cells, e.g. cell-lines, hemopoetic cells, and animal/human tissues (important in therapeutic applications). It will be important to be able to detect the PNA-oligomers that have reacted with their different targets in the individual cells. Labelling with haptens or other reporter molecules of the PNA-oligomer will not be advantageous as this will inhibit (interfere with) the penetration into the cells. Of great significans is the detection of reacted PNA-oligomers, either by immunohistochemistry (in frozen or fixed tissue biopsies) or by Flow-cytometry (e.g. on cells treated with detergent, acetone or alcohol), or in an in vivo set up to detect binding and/or tissue distribution of PNA's added to a cell culture or administered to a living animal.
  • immunohistochemistry in frozen or fixed tissue biopsies
  • Flow-cytometry e.g. on cells treated with detergent, acetone or alcohol
  • PNA-oligomers molecules in which the backbone is structurally homomorphous with the deoxyribose backbone of DNA and which consists of N-(2-aminoethyl)glycin units to which nucleobases are attached through a methylenecarbonyl linker, were synthesized and purified as described in "Improved Synthesis, Purification and characterization of PNA Oligomers", presented at the 3rd Solid-Phase Symposium, Oxford UK, Aug. 31 - Sept. 4, 1994, and by M. Egholm et al., J. Am. Chem. Soc. 114, 1895-1897 (1992) and M. Egholm et al.,J. Chem. Soc. chem.
  • the base sequence of the PNA used is preferably virtually non-self-complementary in order to avoid self-hybridization in the PNA molecule.
  • the number of purines and pyrimidines is approximately equal to allow formation of a double helix configuration rather than a triple helix configuration.
  • DNA oligomers were synthesized on an abi 381A DNA synthesizer from Applied Biosystems using a standard 381A cycle/procedure .
  • the monomers used were standard ⁇ -cyanoethyl phosphoamidites for Applied Biosystems Synthesizer
  • the antigen used for immunizing rabbits was made adding one mol of a 45-mer synthetic polydeoxyribonucleotide (DNA) and three mols of a 15-mer PNA oligomer.
  • the 45-mer polydeoxyribonucleotide was designed as three repeated units of 15 nucleotides and the 15-mer PNA oligomer had a base sequence complementary to the base sequence of the 15-mer unit of the polydeoxyribonucleotide.
  • the base sequence of the 45-mer polydeoxyribonucleotide was as follows:
  • the base sequence of the 15-mer PNA oligomer was as follows:
  • Antigen for immunization of rabbits was prepared by mixing the following in a total volume of 6.01 mL:
  • a ratio of 1 OD of the 45-mer DNA to 1 OD of the 15-mer PNA oligomer is equivalent to a molar ratio of approximately 1:3 using the same extinction coefficient for DNA and PNA.
  • the mixture was heated to 92°C in a heating block and allowed to cool slowly to room temperature. This solution was evaporated in a vacuum centrifuge and resuspended in 600 ⁇ L H 2 O. Final concentration of PNA/DNA hybrid was approximately 10 mg/mL.
  • PNA oligomers labelled with biotin are produced by using the "solid phase” principle for Boc synthesis.
  • a linker comprising two units of 2-(aminoethoxy)ethoxy acetic acid (AEEA) is attached to the PNA oligomer on the resin (see above), and biotin is attached in the following way.
  • Two solutions were used.
  • the first solution contained 0.1 M biotin in 5% 5-collidin in DMF with 2 equivalents of N-ethyldicyclohexylamine and the second solution contained 0.18 M HBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) in DMF.
  • the two solutions were mixed in a ratio of 2 to 1 and the mixture was left for approximately one minute before it was combined with the resin to which the PNA oligomer with two units of AEEA were attached.
  • RNA oligomer was purchased from "DNA Technology Aps, Science Park Aarhus, Gustav Wieds vej 10, DK-8000 Aarhus.
  • 0.1 mL ovalbumin solution (10 mg Sigma A-7641 lot 70H8210 per mL of 0.1 M NaCl, 0.015 M NaN 3 ) and 0.01 mL 1.5 M NaN 3 and this mixture was stepwise whirl mixed into 0.5 mL Titermax #R1 adjuvant (Vaxcel Inc., Norcross, Georgia, USA). Before immunization the volume of this immunization composition was either approximately 1 mL (the first four immunizations) or adjusted to 2 mL (the following immunizations) by addition and mixing with 0.1 M NaCl, 0.015 M NaN 3 .
  • Sera taken before immunization and 10 weeks after immunization of five rabbits were analyzed in the test systems described in example 2.
  • the sera were diluted 2 fold starting at 1:250 (1:250, 1:500, 1:1000, 1:2000, 1:4000, 1:8000, 1:16000, 1:32000) and horseradish peroxidase conjugated swine anti rabbit immunoglobulin was used for visualization.
  • table 1 the results from one representative experiment are shown.
  • the optical density at 492 nm gained by diluting the antibodies 1:500 is shown in tests of sera using the test complexes/compounds A, B, C, D, E, F, G, H, I and J described in example 2.
  • Sera was also testet in a filter dot assay using the test complexes/compounds A, H and J described in example 2 and the individual PNA, DNA and RNA strands included in these complexes. Also two preparations of dsDNA, one consisting of two complementary oligonucleotides and a plasmid DNA, were analysed in this dot blot assay.
  • the test compounds were dotted in amounts of 20, 10, 5 or 2.5 ng on filters, followed by sera diluted 1:2000 in 0.5% casein in TS-buffer (50 mM Tris-HCl, 500 mM NaCl, pH 9.0) and the antibody captured by the test compounds on the filters was visualized with alkaline phosphatase conjugated goat anti rabbit Ig. Only positive reaction was seen with the PNA/DNA complex A in example 2 at a detection limit of 5 ng.
  • Sera was tested in a Southern blot format. Three sets of four different DNA oligonucleotides were loaded on a denaturing 20% polyacrylamide gel. Two of the DNA oligonucleotides used are as described in A and F1 in example 2 and the other two were unrelated DNA oligomers. After electrophoresis the DNA oligonucleotides were transferred to Nytran, nitrocellulose membranes. One filter was hybridized with the PNA oligomer described in A (from example 2), one filter with the PNA oligomer described in F1 (example 2) and the last filter with a mixture of these two PNA oligomers.
  • the membranes were incubated 2 hours at 30 °C with the polyclonal antibody according to the invention (diluted 1:2000). Bound antibody was visualized using alkaline phosphatase conjugated goat anti rabbit Ig and the substrate NBT/BCIP. Only the lanes containing DNA oligonucleotides complementary to the PNA oligomer used for hybridization gave rise to a band with a position as expected for the size of the DNA oligonucleotides used. Thus the polyclonal antibody according to the invention recognizes the PNA/DNA complexes formed in a Southern blot on the nitrocellulose membranes.
  • PNA comprising a N-(2-aminoethyl)glycin backbone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Claims (14)

  1. Anticorps polyclonal, caractérisé en ce qu'il se fixe avec un degré élevé de spécificité à des complexes formés entre l'APN (Acide Peptide Nucléique) (ou PNA pour Peptide Nucléic Acid) et des acides nucléiques.
  2. Anticorps suivant la revendication 1, caractérisé en ce qu'il ne se fixe pas, dans quelque mesure significative que ce soit, à l'APN à brin unique, à l'acide nucléique à double brins ou à l'acide nucléique à brin unique.
  3. Anticorps suivant la revendication 2, caractérisé en ce qu'il se fixe à un complexe formé entre l'APN et l'ADN, mais pas à des complexes APN/ARN, à l'ADN à double brins, à des hybrides ADN/ARN, à l'APN à brin unique ou à un acide nucléique à brin unique.
  4. Anticorps suivant la revendication 2, caractérisé en ce qu'il se fixe à un complexe formé entre l'APN et l'ARN, mais pas à des complexes APN/ADN, à l'ADN à double brins, à des hybrides ADN/ARN, à l'APN à brin unique ou à un acide nucléique à brin unique.
  5. Anticorps suivant l'une quelconque des revendications 1 à 3, caractérisé en ce qu'il peut être obtenu en immunisant un animal hôte avec un complexe formé entre l'APN comportant un squelette de N-(2-aminoéthyle) glycine et l'ADN.
  6. Anticorps suivant l'une quelconque des revendications 1 à 3, et 5, caractérisé en ce qu'il se fixe à des complexes APN/ADN indépendamment de la séquence de base.
  7. Anticorps suivant la revendication 1 ou 2, caractérisé en ce qu'il peut être obtenu en immunisant un animal hôte avec un complexe formé entre l'APN ayant un squelette de N-(2-aminoéthyle) glycine et l'ARN.
  8. Anticorps suivant l'une quelconque des revendications 1 à 7 sous une forme marquée de manière détectable.
  9. Procédé pour détecter une séquence d'acide nucléique particulière dans un échantillon de test, comportant les étapes qui consistent à :
    (a) former un complexe entre la séquence d'acide nucléique particulière à détecter dans l'échantillon et une séquence d'APN qui est complémentaire de la séquence d'acide nucléique à détecter, le complexe ayant au moins un épitope pour un anticorps suivant l'une quelconque des revendications 1 à 8,
    (b) mettre en contact un complexe quelconque qui est formé entre la séquence d'APN et la séquence d'acide nucléique à détecter avec un anticorps suivant l'une quelconque des revendications 1 à 8, et
    (c) déterminer la présence de complexes d'acide nucléique-APN-anticorps.
  10. Procédé suivant la revendication 9, caractérisé en ce que l'anticorps utilisé à l'étape (b) est immobilisé en une phase solide avant d'être mis en contact avec le complexe d'APN-acide nucléique.
  11. Procédé suivant la revendication 9, caractérisé en ce que la séquence APN à l'étape (a) est immobilisée dans un support solide avant d'être mise en contact avec la séquence d'acide nucléique à détecter.
  12. Procédé pour détecter une séquence d'acide nucléique particulière qui existe dans un état immobilisé chez un spécimen biologique, comportant les étapes qui consistent à :
    (a) former un complexe entre l'acide nucléique particulier à détecter chez le spécimen et une séquence d'APN qui est complémentaire de la séquence d'acide nucléique à détecter, le complexe ayant au moins un épitope pour un anticorps suivant l'une quelconque des revendications 1 à 8,
    (b) mettre en contact un complexe quelconque qui s'est formé entre la séquence d'APN et la séquence d'acide nucléique à détecter avec un anticorps suivant l'une quelconque des revendications 1 à 8, et
    (c) déterminer la présence de complexes acide nucléique-APN-anticorps.
  13. Procédé pour détecter une séquence d'acide nucléique particulière dans un échantillon de test, comportant les étapes qui consistent à :
    (a) immobiliser la séquence d'acide nucléique à détecter en une phase solide,
    (b) former un complexe entre la séquence d'acide nucléique particulière à détecter dans l'échantillon et une séquence d'APN qui est complémentaire de la séquence d'acide nucléique à détecter, le complexe ayant au moins un épitope pour un anticorps suivant l'une quelconque des revendications 1 à 8,
    (c) mettre en contact un complexe quelconque qui est formé entre la séquence d'APN et la séquence d'acide nucléique à détecter avec un anticorps suivant l'une quelconque des revendications 1 à 8, et
    (d) déterminer la présence de complexes d'acide nucléique-APN-anticorps.
  14. Trousse de détection d'une séquence d'acide nucléique particulière dans un échantillon, la trousse contenant un anticorps suivant l'une quelconque des revendications 1 à 8, une séquence APN qui est complémentaire à la séquence d'acide nucléique à détecter et un système de détection.
EP95904403A 1993-12-23 1994-12-22 Anticorps polyclonal contre des complexes anp/acide nucleique Expired - Lifetime EP0739356B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK145493 1993-12-23
DK931454A DK145493D0 (da) 1993-12-23 1993-12-23 Antistof
DK1454/93 1993-12-23
PCT/DK1994/000483 WO1995017430A1 (fr) 1993-12-23 1994-12-22 Anticorps polyclonal contre des complexes anp/acide nucleique

Publications (2)

Publication Number Publication Date
EP0739356A1 EP0739356A1 (fr) 1996-10-30
EP0739356B1 true EP0739356B1 (fr) 2000-06-28

Family

ID=8105000

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95904403A Expired - Lifetime EP0739356B1 (fr) 1993-12-23 1994-12-22 Anticorps polyclonal contre des complexes anp/acide nucleique

Country Status (7)

Country Link
US (1) US5612458A (fr)
EP (1) EP0739356B1 (fr)
JP (1) JPH09506872A (fr)
AU (1) AU1310495A (fr)
DE (1) DE69425072T2 (fr)
DK (2) DK145493D0 (fr)
WO (1) WO1995017430A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169169B1 (en) * 1994-05-19 2001-01-02 Dako A/S PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis
US6475721B2 (en) * 1995-03-04 2002-11-05 Boston Probes, Inc. Sequence specific detection of nucleic acids using a solid carrier bound with nucleic acid analog probes
AU4327196A (en) * 1995-06-22 1996-05-31 Dako A/S Monoclonal antibody capable of binding to pna/nucleic acid complexes
JPH11511642A (ja) * 1995-06-22 1999-10-12 ダコ アクティーゼルスカブ Ｐｎａ／核酸複合体に結合し得る組換え抗体
US5888733A (en) * 1995-11-16 1999-03-30 Dako A/S In situ hybridization to detect specific nucleic acid sequences in eucaryotic samples
DE19644302A1 (de) * 1995-11-28 1997-06-05 Boehringer Mannheim Gmbh Verfahren zum Nachweis von Telomerase-Aktivität
US6110676A (en) * 1996-12-04 2000-08-29 Boston Probes, Inc. Methods for suppressing the binding of detectable probes to non-target sequences in hybridization assays
US6083763A (en) * 1996-12-31 2000-07-04 Genometrix Inc. Multiplexed molecular analysis apparatus and method
US20030165953A1 (en) * 1997-07-09 2003-09-04 Isao Karube Method for detecting DNA with probe PNA
US6342350B1 (en) * 1997-09-05 2002-01-29 The General Hospital Corporation Alpha-2-macroglobulin diagnostic test
US6746868B1 (en) 1997-09-18 2004-06-08 Isis Pharmaceuticals, Inc. Chemical modification of DNA using peptide nucleic acid conjugates
WO1999013719A1 (fr) * 1997-09-18 1999-03-25 Gene Therapy Systems, Inc. Modification chimique d'adn a l'aide de conjugues d'acide nucleique peptidique
DE19741716A1 (de) * 1997-09-22 1999-03-25 Hoechst Ag Adressierbares modulares Erkennungssystem, seine Herstellung und Verwendung
US6962778B1 (en) 1997-09-25 2005-11-08 Boston Probes, Inc. Methods, kits and compositions for suppressing the binding of detectable probes to non-target sequences in hybridization assays
US6183956B1 (en) * 1998-03-31 2001-02-06 Tularik, Incorporated High throughput in vitro screening assays for transcription modulators
WO1999050460A1 (fr) * 1998-03-31 1999-10-07 Tularik, Inc. DOSAGE A HAUT RENDEMENT POUR LA DETECTION D'ARNm DANS LES CELLULES
US6287772B1 (en) * 1998-04-29 2001-09-11 Boston Probes, Inc. Methods, kits and compositions for detecting and quantitating target sequences
US6601371B1 (en) 1998-05-05 2003-08-05 Erwin Fertig Packaging machine
US6664045B1 (en) * 1998-06-18 2003-12-16 Boston Probes, Inc. PNA probes, probe sets, methods and kits pertaining to the detection of microorganisms
EP1137807B1 (fr) * 1998-12-08 2004-09-08 Boston Probes, Inc. Methodes, trousses et compositions aux fins de l'identification d'acide nucleiques fixes a des matrices par electricite statique
US6441152B1 (en) * 1998-12-08 2002-08-27 Boston Probes, Inc. Methods, kits and compositions for the identification of nucleic acids electrostatically bound to matrices
US6605648B1 (en) * 1999-04-06 2003-08-12 Phillips Plastics Corporation Sinterable structures and method
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
US7439016B1 (en) * 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
DE60138916D1 (de) * 2000-09-26 2009-07-16 Boston Probes Inc Sonden, sondensätzen,verfahren und kits zur nachweis, identifizierung und/oder die zählung von bakterien
ATE449339T1 (de) * 2000-11-30 2009-12-15 Boston Probes Inc Verfahren und zusammensetzungen zum aussortieren und/oder nachweis von mikroorganismen
JP4408628B2 (ja) * 2001-03-09 2010-02-03 ボストン プローブス，インコーポレイテッド 組み合わせオリゴマーならびにそれらの調製のためのライブラリーに適する、方法、キット、および組成物
AU2002257284A1 (en) 2001-05-18 2002-12-03 Boston Probes, Inc. Pna probes, probe sets, methods and kits pertaining to the detection of candida
EP1487858A4 (fr) * 2002-03-21 2006-01-04 Boston Probes Inc Oligomeres pna, ensembles d'oligomeres, procedes et trousses relatifs a la detection de bacillus anthracis
US20030211509A1 (en) * 2002-03-26 2003-11-13 Wiley Steven R. TNF-delta ligand and uses thereof
WO2003100076A2 (fr) * 2002-05-17 2003-12-04 Applera Corporation Sondes de peptides pna, ensemble de sondes, procede et necessaires se rapportant a la determination des listeria
CA2506805A1 (fr) 2002-11-21 2004-06-10 Epicentre Technologies Corporation Procedes d'utilisation d'amorces qui codent un brin d'un promoteur bicatenaire
DE602005022239D1 (de) * 2004-04-23 2010-08-19 Conjuchem Biotechnologies Inc Festphase zur Verwendung in einem Verfahren zur Reinigung von Albuminkonjugaten
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CA2634495A1 (fr) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Procede de production de conjugues d'albumine preformes et agent therapeutique
EP2231191A2 (fr) * 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation de conjugués de peptides insulinotropes
WO2010062556A1 (fr) 2008-10-27 2010-06-03 Qiagen Gaithersburg Inc. Essai et système de capture d’hybride à résultats rapides
CN102414327B (zh) 2009-05-01 2015-04-08 奇亚根盖瑟斯堡股份有限公司 用于在样品中检测rna剪接形式的非靶向扩增方法
CA2773320C (fr) 2009-09-14 2018-02-20 Qiagen Gaithersburg, Inc. Compositions et methodes pour la recuperation d'acides nucleiques ou de proteines a partir d'echantillons de tissus fixes dans des milieux de cytologie
US9605303B2 (en) 2010-01-29 2017-03-28 Qiagen Gaithersburg, Inc. Method of determining and confirming the presence of an HPV in a sample
US9689047B2 (en) 2010-01-29 2017-06-27 Qiagen Gaithersburg Inc. Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
AU2011255638B2 (en) 2010-05-19 2016-08-25 Qiagen Gaithersburg, Inc. Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
EP2576840B1 (fr) 2010-05-25 2018-10-17 QIAGEN Gaithersburg, Inc. Analyse de capture hybride à résultats rapides et sondes associées tronquées de manière stratégique
JP2014511182A (ja) 2011-02-24 2014-05-15 キアゲン ガイサーズバーグ アイエヌシー． Ｈｐｖ核酸を検出するための材料及び方法
WO2014030066A2 (fr) 2012-08-22 2014-02-27 Bernitz Mats Nilsson Procédés pour identifier des séquences d'acide nucléique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4623627A (en) * 1983-08-19 1986-11-18 Cetus Corporation Monoclonal antibody having specificity for the double-stranded conformation of native DNA and diagnostic methods using same
ZA853756B (en) * 1984-06-01 1986-01-29 Miles Lab Nucleic acid hybridization assay employing immobilized rna probes
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
MX9207334A (es) * 1991-12-18 1993-08-01 Glaxo Inc Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene

Also Published As

Publication number Publication date
US5612458A (en) 1997-03-18
AU1310495A (en) 1995-07-10
JPH09506872A (ja) 1997-07-08
DE69425072D1 (de) 2000-08-03
WO1995017430A1 (fr) 1995-06-29
EP0739356A1 (fr) 1996-10-30
DE69425072T2 (de) 2001-03-08
DK145493D0 (da) 1993-12-23
DK0739356T3 (da) 2000-10-30

Similar Documents

Publication Publication Date Title
EP0739356B1 (fr) Anticorps polyclonal contre des complexes anp/acide nucleique
EP0219695B1 (fr) Immobilisation d'acides nucléiques dans les supports de nylon solvolysé
US4806546A (en) Immobilization of nucleic acids on derivatized nylon supports
EP1110086B1 (fr) Production d'anticorps specifiques d'un motif et independants du contexte au moyen de banques de peptides utilisees comme antigenes
US5464746A (en) Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives
JP5753775B2 (ja) 化学合成した核酸の純度を測定する方法と組成物
EP0405913B1 (fr) Sonde d'acide nucléique hydrophobe
JPH07215995A (ja) 抗原性オリゴペプチドの製造方法
JP5208813B2 (ja) 化学的に合成された核酸の純度を決定し、かつ化学的に合成された核酸を精製するための方法および組成物
JP6901561B2 (ja) 新規のビオチン特異的モノクローナル抗体およびその使用
WO1996014341A1 (fr) Anticorps monoclonal pouvant se fixer a des complexes de pna/acides nucleiques
WO1996012397A2 (fr) Anticorps de recombinaison pouvant se lier a des complexes acides nucleiques/pna
JP3849001B2 (ja) 抗−２′−デオキシシチジン抗体並びにその製造及び使用
AU2002318434A1 (en) Methods and compositions for determining the purity of and purifying chemically synthesized nucleic acids
KR100336620B1 (ko) 안티-ｄｎａ 자가항체에 특이적으로 결합하는 ｒｎａ분자
WO2005007851A1 (fr) Anticorps d'adn et ses utilisations
Rasmussen et al. Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence
EP0598108A1 (fr) Anticorps de lapin a domaine unique et son utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960702

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE DK FR GB IT NL SE

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 19990813

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE DK FR GB IT NL SE

REF Corresponds to:

Ref document number: 69425072

Country of ref document: DE

Date of ref document: 20000803

ITF It: translation for a ep patent filed

Owner name: FUMERO BREVETTI S.N.C.

ET Fr: translation filed
REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20021126

Year of fee payment: 9

Ref country code: NL

Payment date: 20021126

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040701

EUG Se: european patent has lapsed
NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20040701

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20041215

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20041217

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20041228

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20050131

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051222

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060701

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20051222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060831

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20060831